All In Biotech

Drug Trial Radar · NCT07467213

Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction

Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Jun 23, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Samsung Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).

Conditions

  • Acute Myocardial Infarction (AMI)
  • Gastrointestinal Bleeding

Interventions

  • ZastaprazanDrug

    Zastaprazan citrate 20mg will be administered orally once daily for gastrointestinal protection according to the study protocol.

  • Proton Pump Inhibitors (PPI)Drug

    Guideline-directed gastrointestinal protection using various proton pump inhibitors as determined by the physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Net Adverse Clinical Events (NACE)Time frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.